Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Rand. Trial Comp Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine, and Prednisone) in Patients With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment

NCT00774202 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT00774202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00774202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Rand. Trial Comp Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine, and Prednisone) in Patients With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 2/3
Overall status
Completed
Start date
November 30, 2003
Completion date
February 29, 2008
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenic purpura